Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
about
Modulatory effects of bortezomib on host immune cell functionsProteasome inhibitors block DNA repair and radiosensitize non-small cell lung cancerTrial Watch: Proteasomal inhibitors for anticancer therapyPeptide-mediated liposomal Doxorubicin enhances drug delivery efficiency and therapeutic efficacy in animal modelsPhase-I/II study of bortezomib in combination with carboplatin and bevacizumab as first-line therapy in patients with advanced non-small-cell lung cancerLeucovorin Enhances the Anti-cancer Effect of Bortezomib in Colorectal Cancer Cells.The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumorsOverview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.Carfilzomib demonstrates broad anti-tumor activity in pre-clinical non-small cell and small cell lung cancer models.New molecular targeted therapies for advanced non-small-cell lung cancer.Immunohistochemical analysis of the ubiquitin-conjugating enzyme UbcH10 in lung cancer: a useful tool for diagnosis and therapy.Combined bortezomib-based chemotherapy and p53 gene therapy using hollow mesoporous silica nanospheres for p53 mutant non-small cell lung cancer treatment.Bortezomib Improves Adoptive T-cell Therapy by Sensitizing Cancer Cells to FasL Cytotoxicity.From bortezomib to other inhibitors of the proteasome and beyond.Novel compounds in the treatment of lung cancer: current and developing therapeutic agents.Targeted therapies in non-small cell lung carcinoma: what have we achieved so far?Inhibitors for the immuno- and constitutive proteasome: current and future trends in drug development.Efficacy of therapy with bortezomib in solid tumors: a review based on 32 clinical trials.Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types.Bax is involved in the anticancer activity of Velcade in colorectal cancer.2-Aminoethoxydiphenylborane sensitizes anti-tumor effect of bortezomib via suppression of calcium-mediated autophagy.
P2860
Q26795618-96F3D563-8661-4BFE-863B-F5393D5A67E0Q27307731-C664A0E5-8E96-4E8F-9507-2F3EF42C5003Q28082910-F65BA07C-74B6-4B12-88DD-5E89FF305ABAQ28538039-7A2566E8-A702-454A-9FEC-8258EDDDF5DEQ33400938-3AFBDF5C-FDDD-477A-92DD-6D3BABF27030Q33677971-712A1FD3-57E9-4350-9DC0-E960B1D2B344Q34218976-055CE5B2-A164-4C8E-B24A-6656C899C1BEQ34788381-1A35E6A1-7B55-4C23-A108-3B37951EB48FQ35005087-317E2BFA-93C5-4ECD-A66A-F310361C6280Q35667806-EBDC4421-02C2-4458-8B0D-D171B369DDECQ35956214-3288EC42-1956-4C16-BDD3-2325BACECC65Q36185176-571F7A8C-BFEA-4306-B8A6-C956A3E0D89DQ36378038-8A3E4710-BE76-401D-A9F3-9CCE51F19333Q36852277-D08D16A8-C8E4-4840-A61E-E8A8E737C570Q36890658-80F95535-374E-422D-9BBF-903FB243DAC7Q36999705-F5A712FB-B736-41E7-9B3C-9FAB2FB98149Q38019864-5A3A4BE2-BA0A-4C70-9294-825573D0CE06Q38258843-787A8DF8-0441-49D6-AC7A-530133FD7827Q39748970-70EB966D-2715-4991-9872-7DDC9C0DB92EQ41623743-6B8A7BB7-FF3F-4256-B810-40C0D96E9430Q52676389-23FD620F-3476-4793-A27E-A5BE840A533D
P2860
Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC).
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase II study of the proteaso ...... mall cell lung cancer (NSCLC).
@ast
Phase II study of the proteaso ...... mall cell lung cancer (NSCLC).
@en
type
label
Phase II study of the proteaso ...... mall cell lung cancer (NSCLC).
@ast
Phase II study of the proteaso ...... mall cell lung cancer (NSCLC).
@en
prefLabel
Phase II study of the proteaso ...... mall cell lung cancer (NSCLC).
@ast
Phase II study of the proteaso ...... mall cell lung cancer (NSCLC).
@en
P2093
P1433
P1476
Phase II study of the proteaso ...... mall cell lung cancer (NSCLC).
@en
P2093
Bilal Piperdi
Fernando J Camacho
James R Rigas
Liawaty Ho
Rasim Gucalp
Roman Perez-Soler
Tarek Elrafei
Tianhong Li
P356
10.1016/J.LUNGCAN.2009.05.009
P577
2009-06-12T00:00:00Z